We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Expanded access is no longer available for this treatment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01776996
First Posted: January 28, 2013
Last Update Posted: April 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
ViiV Healthcare
January 24, 2013
January 28, 2013
April 6, 2017
 
An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical benefit.
Not Provided
Expanded Access
, Intermediate-size Population
Drug: Continued Access Arm
All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
Not Provided
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Argentina,   Belgium,   Italy,   Poland,   Russian Federation,   South Africa,   Switzerland
 
 
NCT01776996
ViiV Healthcare
ViiV Healthcare
GlaxoSmithKline
Study Director: GSK Clinical Trials ViiV Healthcare
ViiV Healthcare
April 2017